Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

NCT04961359 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus

Interventions

BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) group
BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cells) placebo group

Sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.